Antibe Therapeutics downgraded to Hold from Buy at Maxim

Maxim analyst Jason McCarthy downgraded Antibe Therapeutics to Hold from Buy, stating that an unfavorable arbitration ruling likely delays clinical operations and makes the path forward “unclear.”